SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Sabri Osama))
 

Sökning: (WFRF:(Sabri Osama)) > (2021) > Clinical validity o...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005171naa a2200541 4500
001oai:lup.lub.lu.se:0807754e-355c-4778-8398-b1d7710767cf
003SwePub
008211210s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:145907514
0247 a https://lup.lub.lu.se/record/0807754e-355c-4778-8398-b1d7710767cf2 URI
0247 a https://doi.org/10.1007/s00259-020-05156-42 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1459075142 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Bischof, Gérard N.u University Hospital of Cologne4 aut
2451 0a Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
264 c 2021-02-16
264 1b Springer Science and Business Media LLC,c 2021
300 a 11 s.
520 a Purpose: In 2017, the Geneva Alzheimer’s disease (AD) strategic biomarker roadmap initiative proposed a framework of the systematic validation AD biomarkers to harmonize and accelerate their development and implementation in clinical practice. Here, we use this framework to examine the translatability of the second-generation tau PET tracers into the clinical context. Methods: All available literature was systematically searched based on a set of search terms that related independently to analytic validity (phases 1–2), clinical validity (phase 3–4), and clinical utility (phase 5). The progress on each of the phases was determined based on scientific criteria applied for each phase and coded as fully, partially, preliminary achieved or not achieved at all. Results: The validation of the second-generation tau PET tracers has successfully passed the analytical phase 1 of the strategic biomarker roadmap. Assay definition studies showed evidence on the superiority over first-generation tau PET tracers in terms of off-target binding. Studies have partially achieved the primary aim of the analytical validity stage (phase 2), and preliminary evidence has been provided for the assessment of covariates on PET signal retention. Studies investigating of the clinical validity in phases 3, 4, and 5 are still underway. Conclusion: The current literature provides overall preliminary evidence on the establishment of the second-generation tau PET tracers into the clinical context, thereby successfully addressing some methodological issues from the tau PET tracer of the first generation. Nevertheless, bigger cohort studies, longitudinal follow-up, and examination of diverse disease population are still needed to gauge their clinical validity.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
653 a Alzheimer’s disease
653 a Biomarker-based diagnosis
653 a Second-generation tau PET tracers
653 a Strategic roadmap
7001 a Dodich, Alessandrau University of Geneva,University of Trento4 aut
7001 a Boccardi, Marinau German Center for Neurodegenerative Diseases (DZNE), Bonn4 aut
7001 a van Eimeren, Thilou German Center for Neurodegenerative Diseases (DZNE), Bonn,University Hospital of Cologne4 aut
7001 a Festari, Cristinau Centro San Giovanni di Dio Fatebenefratelli4 aut
7001 a Barthel, Henryku Leipzig University4 aut
7001 a Hansson, Oskaru Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)mphy-ohn
7001 a Nordberg, Agnetau Karolinska Institutet,Karolinska Institute4 aut
7001 a Ossenkoppele, Riku Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Vrije Universiteit Amsterdam4 aut0 (Swepub:lu)ri1513os
7001 a Sabri, Osamau Leipzig University4 aut
7001 a Giovanni, B. Frisoni G.u University of Geneva,Geneva University Hospital4 aut
7001 a Garibotto, Valentinau University of Geneva,Geneva University Hospital4 aut
7001 a Drzezga, Alexanderu German Center for Neurodegenerative Diseases (DZNE), Bonn,University Hospital of Cologne4 aut
7102 a University Hospital of Cologneb University of Geneva4 org
7730 t European Journal of Nuclear Medicine and Molecular Imagingd : Springer Science and Business Media LLCg 48:7, s. 2110-2120q 48:7<2110-2120x 1619-7070x 1619-7089
8564 u http://dx.doi.org/10.1007/s00259-020-05156-4x freey FULLTEXT
8564 u https://link.springer.com/content/pdf/10.1007/s00259-020-05156-4.pdf
8564 8u https://lup.lub.lu.se/record/0807754e-355c-4778-8398-b1d7710767cf
8564 8u https://doi.org/10.1007/s00259-020-05156-4
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:145907514

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy